Opportunity Information: Apply for PA 16 036
Apply for PA 16 036
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.837,.
- This funding opportunity was created on Nov 17, 2015 and posted on Nov 17, 2015.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)" (Funding Opportunity Number PA 16-036) is a National Institutes of Health (NIH) discretionary research grant aimed at improving how clinicians and researchers identify, understand, and ultimately reduce heart-related side effects that can occur as a result of cancer therapy. The focus is on cancer treatment-related cardiotoxicity, meaning cardiovascular injury or dysfunction linked to anti-cancer treatments, with the practical goal of protecting heart health without compromising the effectiveness of cancer care. This is positioned as a collaborative effort, encouraging teams that bridge oncology and cardiology (and related disciplines) to develop approaches that better predict risk, detect problems early, and manage complications more effectively.
A central theme of the announcement is risk identification and characterization. Applications are expected to contribute to recognizing which patients are most likely to develop cardiotoxicity, and to clarifying how that risk presents across different patient populations and treatment contexts. Rather than treating cardiotoxicity as an after-the-fact complication, the FOA emphasizes evaluating cardiac risk prior to initiating cancer treatment. That means proposed research may involve new or improved ways to screen patients before therapy begins, stratify them into risk categories, and use that information to guide treatment planning and follow-up care.
The FOA also stresses integration: evidence-based cancer treatment regimens should be paired with appropriate screening, diagnostic, and management strategies aimed at preventing or mitigating cardiovascular dysfunction. In other words, it is not just about discovering biomarkers or building prediction models in isolation; it is also about how those tools would be used alongside real-world cancer treatment plans to reduce harm. The announcement seeks approaches that can be applied during active cancer treatment as well as throughout long-term survivorship, acknowledging that cardiotoxic effects can emerge immediately, accumulate over time, or become apparent years after therapy ends.
The scope of cancer therapies covered is broad and includes traditional cytotoxic chemotherapies, targeted agents, immunomodulatory therapies, and radiation therapy. The adverse cardiac outcomes of interest are those defined using cardiac-specific Common Terminology Criteria for Adverse Events (CTCAE), signaling that applicants should align their endpoints and toxicity definitions with standardized clinical criteria used in oncology research and practice. This emphasis on CTCAE helps ensure that proposed studies speak a common language for grading and tracking cardiovascular adverse events, which is important for comparability and eventual translation into clinical workflows.
Administratively, this is an NIH R21 mechanism, which typically supports early-stage, exploratory, or developmental research that can generate foundational data, validate a promising concept, or establish feasibility for a larger study. The listed award ceiling is $200,000, reflecting the smaller, proof-of-concept nature common to R21 projects. The opportunity was posted on November 17, 2015, created the same day, and shows a closing date of January 7, 2019 (with the same original and current closing date listed in the source information).
Eligibility is wide-ranging and includes many types of domestic organizations that commonly participate in federally funded research. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments as well as other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as listed); for-profit organizations other than small businesses; and small businesses. The sponsoring agency is listed as HHS-NIH11, and the program aligns with CFDA numbers 93.393 and 93.837, which correspond to NIH health research funding areas connected to cancer and heart, lung, and blood research.
Overall, this FOA is designed to stimulate practical, team-based research that reduces the cardiovascular toll of modern cancer therapy. It is geared toward projects that can meaningfully inform clinical decision-making by identifying who is at risk, evaluating risk before treatment begins, and testing integrated strategies for monitoring, diagnosing, and managing cardiotoxicity during treatment and across survivorship, all while keeping cancer outcomes front and center.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)" and the Funding Opportunity Number is PA 16-036.
Which agency is offering this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH), listed as HHS-NIH11.
What type of grant mechanism is this?
This is an NIH R21 mechanism, which is typically used for early-stage, exploratory, or developmental research designed to generate foundational data, validate a concept, or establish feasibility for future work.
What is the primary goal of this FOA?
The primary goal is to improve how clinicians and researchers identify, understand, and reduce heart-related side effects (cardiotoxicity) that can occur as a result of cancer therapy, while protecting heart health without compromising effective cancer care.
What does "cancer treatment-related cardiotoxicity" mean in this FOA?
It refers to cardiovascular injury or dysfunction linked to anti-cancer treatments, including effects that can arise during treatment, accumulate over time, or appear years after therapy ends.
What kinds of research approaches does the FOA emphasize?
The FOA emphasizes practical approaches that support clinical decision-making, including improving risk prediction, enabling early detection, and strengthening monitoring and management strategies for cardiotoxicity in the context of real-world cancer treatment plans.
Does the FOA focus only on discovering biomarkers or prediction models?
No. The FOA specifically stresses integration, meaning research should connect screening, diagnostic, and management strategies with evidence-based cancer treatment regimens, rather than developing tools in isolation.
What is meant by evaluating cardiac risk prior to initiating cancer treatment?
It means proposed research may focus on assessing cardiac risk before therapy begins, potentially through new or improved screening methods, risk stratification approaches, and ways to use that information to guide treatment planning and follow-up care.
Is the FOA interested in differences in risk across patient populations and treatment contexts?
Yes. A central theme is risk identification and characterization, including recognizing which patients are most likely to develop cardiotoxicity and clarifying how risk presents across different patient populations and treatment contexts.
At what points in the cancer care timeline should cardiotoxicity be addressed?
The FOA highlights approaches that can be applied during active cancer treatment as well as throughout long-term survivorship, acknowledging that cardiotoxic effects may occur immediately, develop gradually, or show up years later.
What cancer therapies are within the scope of this FOA?
The scope is broad and includes traditional cytotoxic chemotherapies, targeted agents, immunomodulatory therapies, and radiation therapy.
How should adverse cardiac outcomes be defined for studies under this FOA?
The FOA points to using cardiac-specific Common Terminology Criteria for Adverse Events (CTCAE) to define and grade cardiovascular adverse events, supporting standardized endpoints and comparability across studies.
Why does the FOA emphasize CTCAE for cardiotoxicity outcomes?
Because CTCAE is a standardized clinical framework used in oncology research and practice for grading adverse events. Aligning cardiac endpoints with CTCAE helps studies use a common language that can support comparison and translation into clinical workflows.
What is the maximum award amount mentioned for this opportunity?
The listed award ceiling is $200,000, consistent with the proof-of-concept nature common to R21 projects.
When was this funding opportunity posted and when does it close?
The opportunity was posted on November 17, 2015 (and created the same day). The closing date shown is January 7, 2019, with the same date listed as both the original and current closing date in the provided source information.
Who is eligible to apply for this grant?
Eligibility is broad and includes many domestic organization types, including:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Other Native American tribal organizations
- Public housing authorities
- Indian housing authorities
- Nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as listed)
- For-profit organizations other than small businesses
- Small businesses
Does the FOA encourage collaboration across disciplines?
Yes. It is positioned as a collaborative effort that encourages teams bridging oncology and cardiology (and related disciplines) to develop better ways to predict risk, detect cardiotoxicity early, and manage complications.
What is the practical clinical emphasis of this funding opportunity?
The practical emphasis is on reducing cardiovascular harm from modern cancer therapy by improving risk assessment before treatment, integrating monitoring and management with cancer treatment plans, and supporting patient health during treatment and survivorship without sacrificing cancer outcomes.
Which CFDA numbers are associated with this opportunity?
The program aligns with CFDA numbers 93.393 and 93.837, described in the provided information as NIH health research funding areas connected to cancer and to heart, lung, and blood research.
Browse more opportunities from the same category: Education, Health
Next opportunity: THIS IS NOT A REQUEST FOR APPLICATIONS- NPS TRAIL STUDY SUPPORT INTERN MWRO- THIS IS NOT A REQUEST FOR APPLICATIONS
Previous opportunity: Human Rights Support Mechanism (HRSM)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 036
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 036) also looked into and applied for these:
| Funding Opportunity |
|---|
| Proteogenomic Data Analysis Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 023 Funding Number: RFA CA 15 023 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $675,000 |
| Systems Biology Approaches in HIV/AIDS and Substance Use (R01) Apply for RFA DA 16 013 Funding Number: RFA DA 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Specialized Genomic Data Center (U24) Apply for RFA CA 15 020 Funding Number: RFA CA 15 020 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $330,000 |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 16 009 Funding Number: PAR 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01) Apply for PAR 16 058 Funding Number: PAR 16 058 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R21) Apply for PA 16 011 Funding Number: PA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Image-guided Drug Delivery (R01) Apply for PAR 16 044 Funding Number: PAR 16 044 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Promoting Caregiver Health Using Self-Management (R01) Apply for RFA NR 16 003 Funding Number: RFA NR 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $350,000 |
| Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) Apply for RFA CA 16 003 Funding Number: RFA CA 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Mechanism for Time-Sensitive Drug Abuse Research (R21) Apply for PAR 16 055 Funding Number: PAR 16 055 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Small Cell Lung Cancer (SCLC) Consortium: Coordinating Center (U24 ) Apply for PAR 16 050 Funding Number: PAR 16 050 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 16 002 Funding Number: RFA CA 16 002 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) Apply for RFA CA 16 004 Funding Number: RFA CA 16 004 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01) Apply for PAR 16 049 Funding Number: PAR 16 049 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Genomic Data Analysis Network: Processing Genomic Data Center (U24) Apply for RFA CA 15 018 Funding Number: RFA CA 15 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Apply for RFA NS 16 013 Funding Number: RFA NS 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01) Apply for PAR 16 051 Funding Number: PAR 16 051 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R01) Apply for PA 16 012 Funding Number: PA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 036", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.